Molecular Testing for Targeted Therapy in Advanced XXXX : Suitability of Endobronchial Ultrasound Transbronchial Needle Aspiration.

@entity1 @entity7041 @entity5 @entity470 @entity984 @entity1149 @entity2
OBJECTIVES: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive procedure that has revolutionized the diagnosis and @entity5 . The goal of the present study was to investigate the yield and applicability of molecular testing in the specimens obtained by EBUS-TBNA from @entity1 with advanced @entity1149 ( @entity1149 ), comparing the results with a series of @entity1 who underwent diagnostic surgical procedures in the same institution. METHODS: The study followed 306 consecutive @entity1 with clinically diagnosed primary @entity2 who had the EBUS-TBNA procedure. @entity470 and @entity984 mutations were evaluated on cytologic specimens by Sanger sequencing and Cobas real-time polymerase chain reaction, whereas @entity7041 rearrangement was tested by fluorescence in situ hybridization. The results were compared with those obtained from a series of 1,000 @entity1149 surgical samples routinely analyzed. RESULTS: Molecular testing was possible in 96.9% of the samples obtained by EBUS-TBNA. @entity470 (exons 18-21) mutations were found in 16.9%, @entity984 mutation (exons 2-3) in 31.6%, and @entity7041 rearrangement in 3.9% of the cases. In the surgical series, the mutations' distribution were 14.8%, 29.0%, and 3.4%, respectively. There were no statistical differences between the two series. CONCLUSIONS: Our study demonstrates that EBUS-TBNA can be effectively used not just for diagnosis but also for complete mutational testing.
